08/09/2024 | Press release | Archived content
Quarterly report pursuant to Section 13 or 15(d)
Cover
Cover - shares |
6 Months Ended | |
---|---|---|
Jun. 30, 2024 |
Aug. 09, 2024 |
|
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jun. 30, 2024 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2024 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 001-13341 | |
Entity Registrant Name | Titan Pharmaceuticals, Inc. | |
Entity Central Index Key | 0000910267 | |
Entity Tax Identification Number | 94-3171940 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 400 Oyster Point Blvd. | |
Entity Address, Address Line Two | Suite 505 | |
Entity Address, City or Town | South San Francisco | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94080 | |
City Area Code | (650) | |
Local Phone Number | 244-4990 | |
Title of 12(b) Security | Common Stock, par value $0.001 | |
Trading Symbol | TTNP | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 914,234 |